Adjunct Faculty
Adjunct faculty typically have an academic or research appointment at another institution and contribute or collaborate with one or more School of Medicine faculty members or programs.
Adjunct rank detailsHoward Feldman, MD, FRCPC, FAAN (Neurology)
Professor AdjunctAbout
Copy Link
Research
Copy Link
Overview
Medical Research Interests
Dementia; Information Science; Named Groups
Research at a Glance
Yale Co-Authors
Frequent collaborators of Howard Feldman's published research.
Publications Timeline
A big-picture view of Howard Feldman's research output by year.
Research Interests
Research topics Howard Feldman is interested in exploring.
James Brewer
Godfrey Pearlson, MA, MBBS
Harlan Krumholz, MD, SM
275Publications
13,442Citations
Publications
2026
Safety considerations of gene‐based therapies for Alzheimer's disease
Bevins E, Léger G, Herman M, Ringman J, Roy S, Shtrahman M, Pa J, Feldman H. Safety considerations of gene‐based therapies for Alzheimer's disease. Alzheimer's & Dementia 2026, 22: e71515. PMID: 42427159, PMCID: PMC13351316, DOI: 10.1002/alz.71515.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsAltmetricAutism screening and diagnosis in children with congenital heart disease
Perez N, Rios P, Marchman V, Aishworiya R, Wang S, Feldman H. Autism screening and diagnosis in children with congenital heart disease. Frontiers In Pediatrics 2026, 14: 1839114. DOI: 10.3389/fped.2026.1839114.Peer-Reviewed Original ResearchCitationsAltmetricEfficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials
Cummings J, Atri A, Sano M, Zetterberg H, Scheltens P, Knop F, Johannsen P, Wichmann C, Abschneider R, Leon T, Feldman H. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. The Lancet 2026, 407: 2167-2179. PMID: 41865758, DOI: 10.1016/s0140-6736(26)00459-9.Peer-Reviewed Original ResearchCitationsAltmetricOpportunities and Alternative Approaches for Improving Language Outcomes in Young Children.
Feldman H, Marchman V. Opportunities and Alternative Approaches for Improving Language Outcomes in Young Children. PEDIATRICS 2026, 157 PMID: 41833319, DOI: 10.1542/peds.2025-075539.Peer-Reviewed Original ResearchAltmetricValidation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial
Duehring J, Jacobs D, Salmon D, MacKelfresh A, Revta C, Meyer A, Schaeffer M, Schell-Mader S, Wassmann T, Wenzkowski C, Feldman H, Edland S, Group A. Validation of a novel cognitive-functional outcome measure optimized for early Alzheimer’s Disease: Evidence from the VIVA-MIND trial. The Journal Of Prevention Of Alzheimer's Disease 2026, 13: 100531. PMID: 41830756, PMCID: PMC12996941, DOI: 10.1016/j.tjpad.2026.100531.Peer-Reviewed Original ResearchAltmetricA path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA
Reiman E, Alexander R, Langbaum J, Aisen P, Ashton N, Atri A, Barbarino P, Byrd G, Feldman H, Fowler N, Ghisays V, Grill J, Hassenstab J, Heaton G, Herring W, Jack C, Johnson S, Karlawish J, Keach N, Kivipelto M, Krumholz H, Largent E, MaGee-Rodgers T, McDade E, Mielke M, Molina-Henry D, Petersen R, Rabinovici G, Ritchie C, Schindler S, Sperling R, Suárez-Calvet M, Vradenburg G, Weiner M, Welsh-Bohmer K, Zetterberg H, Zuendel M, Mattke S, Cummings J. A path to preventing cognitive impairment due to Alzheimer's disease: initiatives beginning in the USA. The Lancet Neurology 2026, 25: 268-278. PMID: 41722593, DOI: 10.1016/s1474-4422(25)00483-1.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsCitationsAltmetricRelationships between fine memory discrimination and tau burden in two independent cohorts of older adults
Fenton L, Aslanyan V, Jacobs D, Salmon D, Brewer J, Rissman R, Shadyab A, Harrison T, Evans A, LaCroix A, Feldman H, Baker L, Pa J. Relationships between fine memory discrimination and tau burden in two independent cohorts of older adults. Neuropsychologia 2026, 224: 109393. PMID: 41672403, DOI: 10.1016/j.neuropsychologia.2026.109393.Peer-Reviewed Original ResearchAltmetricGenetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference
Field T, Morton S, Brossard-Racine M, Cohen S, Feldman H, Chung A, Newburger J, Puder R, Gurvitz M, Cassidy A. Genetics and Brain Health in Adults With Congenital Heart Disease: A Consensus Statement From the ACHD/Neuro 2024 Conference. Journal Of The American Heart Association 2026, 15: e042617. PMID: 41553060, PMCID: PMC12919480, DOI: 10.1161/jaha.125.042617.Peer-Reviewed Original ResearchCitationsAltmetricBaseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease
Scheltens P, Atri A, Feldman H, Zetterberg H, Sano M, Johannsen P, Colombo T, Bardtrum L, Jeppesen R, Hansen C, Cummings J. Baseline characteristics from evoke and evoke+: Two phase 3 randomized placebo‐controlled trials of semaglutide in participants with early‐stage symptomatic Alzheimer's disease. Alzheimer's & Dementia: Translational Research & Clinical Interventions 2026, 12: e70200. PMID: 41522368, PMCID: PMC12789876, DOI: 10.1002/trc2.70200.Peer-Reviewed Original ResearchCitationsAltmetric
2025
Family Navigation Engagement and Outcomes for Children With a New Autism Diagnosis
Lin I, Morgan A, Herringshaw A, Lopez N, Deras M, Feldman H. Family Navigation Engagement and Outcomes for Children With a New Autism Diagnosis. Journal Of Autism And Developmental Disorders 2025, 1-11. PMID: 41313578, DOI: 10.1007/s10803-025-07168-1.Peer-Reviewed Original ResearchAltmetric
Get In Touch
Copy Link